期刊文献+

肿瘤干细胞标记物CD44^+CD24^(low/-)与MMP-9在乳腺癌组织中的表达及其意义 被引量:3

Expression and Significance of Tumor Stem Cancer Marker CD44^+CD24^(low/-) and MMP-9 in Breast Cancer
原文传递
导出
摘要 目的研究肿瘤干细胞标记物CD44+CD24low/-以及基质金属蛋白酶-9(MMP-9)的表达与肿瘤临床病理参数之间的关系。方法采用免疫组织化学方法检测109例乳腺癌组织中的CD44、CD24及MMP-9的表达并对结果进行分析。结果(1)109例乳腺癌组织中CD44、CD24及MMP-9的表达率分别是47.7%、50.5%及40.4%,其中CD44的阳性表达率与乳腺癌病理分级密切相关(P<0.05);(2)109例乳腺癌组织中,CD44+CD24low/-肿瘤干细胞标记阳性例数为32例,随乳腺癌病理分级的升高,CD44+CD24low/-肿瘤干细胞比率也明显增加(P<0.05);(3)32例CD44+CD24low/-肿瘤干细胞标记阳性乳腺癌组织中,MMP-9蛋白的表达与淋巴结转移成负相关(P<0.05)。结论高度恶性乳腺癌组织中富于肿瘤干细胞,乳腺癌早期CD44+CD24low/-TSC中MMP-9蛋白表达增加可能对肿瘤干细胞(TSC)生长及浸润中起着一定作用。 Objective To investigate the expression of Cancer Stem Cancer Marker CD44 + CD24low/- and matrix metalloproteinase-9 (MMP-9) in breast cancer and its relationship with the clinical characteristics of tumors. Methods In one hundred and nine cases of breast cancer tissues CD44,CD24 and MMP-9 were detected with immunohistochemisrty. Results ( 1 ) The expression rate of CD44, CD24 and MMP-9 protein was 47.7% ,50.5% and 40.4% in 109 cases of breast cancer respectively. The ex- pression rates of CD44 protein was related with breast cancer pathological grades (P 〈 0.05 ). (2) Thirty two positive cases of CD44 + CD24low/- were detected in 109 cases of breast cancer. The expression of CD44 + CD24low/- was closely related with breast cancer pathologic grades. (3) The expression of MMP-9 protein was in inverse correlations with lymphoid metastasis in CD44 + CD24low/- positive cases (P 〈 0.05 ). Conclusion CD44 + CD24low/- TSC is often be found in poor differentiation breast cancer tissues. And MMP-9 protein can be an important factor in invasion of CD44 + CD24low/- TSC in early stage of breast cancer.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2010年第1期110-113,I0006,共5页 Suzhou University Journal of Medical Science
基金 国家自然科学基金资助项目(30672390) 苏州大学博士基金资助项目(14134803) 苏州市科技发展计划项目(SZD0960)
关键词 肿瘤干细胞 CD4 CD24 基质金属蛋白酶-9 乳腺癌 免疫组织化学技术 tumor stein cell CD44 CD24 matrix metalloproteinase-9 breast cancer immunohistochemistry
  • 相关文献

参考文献10

  • 1Gil J, Stembalska A, Pesz KA, et al. Cancer stem cells: the theory and perspectives in cancer therapy [ J]. J Appl Genet, 2008,49 (2) :193 - 199.
  • 2Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci U S A, 2003,100(7):3983-3988.
  • 3Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stein cell markers selects for breast cancer cells with enhanced malignant and metastatic ability [ J ]. J Cell Mol Med, 2008,4 (4) : 1 -43.
  • 4Pacheco MM, Nishimoto IN, Mour? o Neto M, et al. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis [ J ]. Int J Biol Markers, 2001,16 (1) :62 -68.
  • 5顾丽琴,邓海贞,任苏勤,柴玉海,谢芳.基质金属蛋白酶-9在乳腺癌组织中的表达及生物学意义[J].中国现代医药杂志,2009,11(2):1-3. 被引量:4
  • 6Tavassoeli F A, Devilee P. Pathology and Genetics Tumours of the Breast and Female Genital Organs [ M ]. Lyon : IARC Press, 2003 : 10.
  • 7许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 8Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation [ J]. Cancer Res, 1997, 57(7) :1228 - 1232.
  • 9Madjd Z, Mehrjerdi AZ, Sharifi AM, et al. CD44^+ cancer cells express higher levels of the anti-apoptotic protein Bcl- 2 in breast turnouts [J]. Cancer Immun, 2009, 23(9) :4 -11.
  • 10Bircan S, Kapucuoglu N, Baspinar S, et al. CD24 expression in duetal carcinoma in situ and invasive duetal carcinoma of breast: an immunohistochemistry-based pilot study [ J ]. Pathol Res Praet, 2006,202 ( 8 ) :569 - 576.

二级参考文献12

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2赵彤,朱梅刚,黄宗义,张亚历,张素娟,李梅芳.肺癌癌基因蛋白产物同步检测的对比分析[J].癌症,1995,14(1):13-15. 被引量:54
  • 3谷化平,冯和平,徐志勇,苏红.免疫组化在恶性黑色素瘤诊断中的作用[J].中国肿瘤临床,1996,23(8):599-600. 被引量:4
  • 4Bhuvarahamurthy V,Kristiansen GO,Johannsen M,et al.ln situ gene expression and localization of metalloproteinases MMPI,MMP2,MMP3,MMP9,and theirinhibitors TIMP1 and TIMP2 in human renal cell carcinoma[J].Oncol Rep,2006,15(5):1379-1384
  • 5Tavassoéli,F.A.,Devilee,P.Pathology and Genetics Tumours of the Breast and Female Genital Organs[M].Lyon:IARC Press,2003:10
  • 6Robert C,Millikan,Beth Newman,et al.Epidemiology of basal-like breast cancer[J].Brea.st Cancer Res Treat,2008,109(1):123
  • 7Webb CP,Vande Woude GF.Genes that regulate metastasis and an giogenesis[J].J Neurooncol,2000,50:71-87
  • 8Murphy PM.Chemokines and the molecular basis of cancer metas tasis[J].N Engl J Meal,2001,345(11):833-835
  • 9Fingleton B.Matrix metalloproteinases:roles in cancer and metasta sis[J].Front Biosci,2006,11:479-491
  • 10Struckmann K,Mertz K,Steu S,et al.pVHL co-ordinately regulates CXCR4/CXCI,12 and MMP2/MMP9 expression in human clearcell renal cell carcinoma[J].J Patho 1,2008,214(4):464-471

共引文献1366

同被引文献73

  • 1李治,黄韬,贺艳丽,张家华,田元.对不同性质乳腺组织中乳腺干细胞比例的测定[J].华西医学,2006,21(3):442-444. 被引量:1
  • 2Clayton H, Titley I, Vivanco M. Growth and differentiation of progenitor/stem ceils derived from the human mammary gland [ J]. Exp Cell Res,2004,297(2) :444 -460.
  • 3Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer [ J ]. Cancer Res ,2004,64 ( 17 ) :6071-6074.
  • 4Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates[J]. Annu RevNeurosci ,2002,25:471 -490.
  • 5Doutu G, Patel S, Mantle ID, et al. Role of Notch signaling in cellfate determination of human mammary stem/progenitor cells [ J ]. Breast Cancer Res,2004,6(6) : 605 -615.
  • 6Levi BP,Yilmaz OH, Duester G,et al. Aldehyde dehydrogenase 1 al is dispensable for stem cell function in the mouse hematopoietic and nervous systems [ J ]. Blood,2009,113 (8) : 1670-1680.
  • 7Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer [J]. Ann Onco1,2009,20 (5) :862-867.
  • 8Baselga J,Averbuch SD. ZD1839 ( ' Iressa' ) as an anticancer agent[J]. Drugs,2000,60 Suppl 1:33 -40.
  • 9Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model [J]. Clin Cancer Res, 1995,1 ( 11 ) : 1311 -1318.
  • 10McKillop D, Partridge EA, Kemp JV, et al. Tumor penetration of gefitinib ( Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Mol Cancer Ther,2005,4 (4) :641-649.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部